Noven Announces 2007 Third Quarter Earnings Release Date

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced its 2007 third quarter earnings release date.

On November 8th, before the U.S. market opens, Noven is scheduled to issue a press release announcing its financial results for the three and nine month periods ended September 30, 2007. At 9:00 a.m. Eastern Time the same day, a conference call with management will be broadcast live via the Internet at www.noven.com, and thereafter a rebroadcast will be accessible at the same site for at least two weeks. A taped replay of the call will be available beginning November 8th through November 10th by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering account number 286 and conference ID number 258318.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, has established itself as a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Its commercialized transdermal products include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD.

With the acquisition of JDS Pharmaceuticals in August 2007, Noven has become a broader-based specialty pharmaceutical company with the infrastructure, products and category expertise to market and sell products itself, and with a substantially enhanced late-stage product pipeline.

Products currently marketed through the JDS psychiatry sales infrastructure consist of Pexeva® (paroxetine mesylate) and Lithobid® (lithium carbonate). Pipeline products in psychiatry consist of Stavzor™ (delayed release valproic acid capsule), Lithium QD (once-daily lithium carbonate), and Stavzor™ ER (extended release valproic acid capsule). Pipeline products in women’s health consist of Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product entering Phase 3 clinical trials for vasomotor symptoms (hot flashes). See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916